Suzhou Motif Biotech Co., Ltd. is situated in the Suzhou High-tech Zone (Huqiu District), serving as an innovative biotech firm dedicated to the research, development, and production of peptide-related products. Established in 2021, the company commenced its research and manufacturing operations in March 2023.
By the onset of 2024, Motif Biotech had invested approximately 100 million yuan in its research and development (R&D) endeavors. Spanning across an area of approximately 4,300 square meters, Suzhou Motif Biotech boasts over a hundred research and development laboratories, with a planned annual production capacity of 30 kilograms. Furthermore, the company has instituted a GMP workshop covering approximately 800 square meters, meticulously adhering to the guidelines outlined in ICHQ7. The production and quality standards of its peptide drugs comply with the regulations of the FDA, EMA, and NMPA.
Leveraging decades of experience in peptide synthesis among its founders and R&D team, Motif Biotech can produce over 95% of custom peptides available in the market. This is achieved through a comprehensive process involving peptide drug design and screening, followed by drug coupling, modification, and optimization. The contract research organization (CRO) and contract development and organization (CDMO) divisions at Motif Biotech deliver premium-quality services with efficiency and competitive pricing.
The integrated CRDMO (CRO/CDMO) platform at Motif Biotech offers customizable services for peptide drugs, spanning from early drug discovery to preclinical research and clinical trial sample production. Employing solid-phase, liquid-phase, and solid/liquid-phase synthesis techniques, the company produces bioactive peptides tailored for various applications and sizes. Motif Biotech is steadfast in its commitment to enhancing the efficiency of peptide drug R&D for its global clientele, encompassing both innovative and generic solutions.
At Motif, the core values of "Successful customers, successful employees, successful company" remain perpetual. The projected production capacity of its R&D operations is anticipated to exceed 100 kilograms. Looking ahead, Motif aims to expand its industrial CRDMO footprint by leveraging peptide technology licenses for peptide–drug conjugates (PDC), antibody-drug conjugates (ADC), and nucleic acid drugs, thereby solidifying its position as a leading global entity in the peptide CRDMO domain.